Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review

<p>Abstract</p> <p>Background</p> <p>Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.</p> <p>Results</p> <p>To evaluate the comparison of the efficacy of LAM and LdT in the treatment of chronic hepatitis B by a systematic review and meta-analysis of clinical trials, we searched PUBMED (from 1990 to April 2010), Web of Science (from 1990 to April 2010), EMBASE (from 1990 to April 2010), CNKI (National Knowledge Infrastructure) (from 1990 to April 2010), VIP database (from 1990 to April 2010), WANFANG database (from 1990 to April 2010), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. At the end of one-year treatment, LdT was better than LAM at the biochemical response, virological response, HBeAg loss, therapeutic response, while less than at the viral breakthrough and viral resistance, but there was no significant difference in the HBeAg seroconversion and HBsAg response. LdT was better than LAM at the HBeAg seroconversion with prolonged treatment to two years.</p> <p>Conclusions</p> <p>In summary, LdT was superior in inhibiting HBV replication and preventing drug resistance as compared to LAM for CHB patients. But LdT may cause more nonspecific adverse events and can lead to more CK elevation than LAM. It is thus recommended that the LdT could be used as an option for patients but adverse events, for example CK elevation, must be monitored.</p

Impact of the Interaction between 3′-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes

Genetic variation in the expression of human XMETs leads to inter-individual variability in metabolism of therapeutic agents as well as differed susceptibility to various diseases. Recent eQTL (expression quantitative traits loci) mapping in a few human cells/tissues have identified a number of SNPs significantly associated with mRNA expression of many XMET genes. These eQTLs are therefore important candidate markers for pharmacogenetic studies. However, questions remain about whether these SNPs are causative and in what mechanism these SNPs may function. Given the important role of microRNAs in gene transcription regulation, we hypothesize that those eQTLs or their proxies in strong linkage disequilibrium (LD) altering microRNA targeting are likely causative SNPs affecting gene expression. The aim of this study is to identify eQTLs potentially regulating major XMETs via interference with microRNA targeting. To this end, we performed a genome-wide screening for eQTLs for 409 genes encoding major drug metabolism enzymes transporters and transcription factors, in publically available eQTL datasets generated from the HapMap lymphoblastoid cell lines (LCLs) and human liver and brain tissue. As a result, 308 eQTLs significantly (p&lt;10-5) associated with mRNA expression of 101 genes were identified. We further identified 7,869 SNPs in strong LD (r2≥0.8) with these eQTLs using the 1000 Genome SNP data. Among these 8,177 SNPs, 27 are located in the 3’-UTR of 14 genes. Using two algorithms predicting microRNA-SNP interaction, we found that almost all these SNPs (26 out of 27) were predicted to create, abolish or change the target site for microRNAs in both algorithms. Many of these microRNAs were also expressed in the same tissue that the eQTL were identified. Our study provides a strong rationale for continued investigation for the functions of these eQTLs in pharmacogenetic settings

The Use of Nanoscaled Fibers or Tubes to Improve Biocompatibility and Bioactivity of Biomedical Materials

Nanofibers and nanotubes have recently gained substantial interest for potential applications in tissue engineering due to their large ratio of surface area to volume and unique microstructure. It has been well proved that the mechanical property of matrix could be largely enhanced by the addition of nanoscaled fibers or tubes. At present, more and more researches have shown that the biocompatibility and bioactivity of biomedical materials could be improved by the addition of nanofibers or nanotubes. In this review, the efforts using nanofibers and nanotubes to improve biocompatibility and bioactivity of biomedical materials, including polymeric nanofibers/nanotubes, metallic nanofibers/nanotubes, and inorganic nanofibers/nanotubes, as well as their researches related, are demonstrated in sequence. Furthermore, the possible mechanism of improving biocompatibility and bioactivity of biomedical materials by nanofibers or nanotubes has been speculated to be that the specific protein absorption on the nanoscaled fibers or tubes plays important roles

Metadata Caching in Presto: Towards Fast Data Processing

Presto is an open-source distributed SQL query engine for OLAP, aiming for "SQL on everything". Since open-sourced in 2013, Presto has been consistently gaining popularity in large-scale data analytics and attracting adoption from a wide range of enterprises. From the development and operation of Presto, we witnessed a significant amount of CPU consumption on parsing column-oriented data files in Presto worker nodes. This blocks some companies, including Meta, from increasing analytical data volumes. In this paper, we present a metadata caching layer, built on top of the Alluxio SDK cache and incorporated in each Presto worker node, to cache the intermediate results in file parsing. The metadata cache provides two caching methods: caching the decompressed metadata bytes from raw data files and caching the deserialized metadata objects. Our evaluation of the TPC-DS benchmark on Presto demonstrates that when the cache is warm, the first method can reduce the query's CPU consumption by 10%-20%, whereas the second method can minimize the CPU usage by 20%-40%.Comment: 5 pages, 8 figure

Lifestyle and metabolic factors for nonalcoholic fatty liver disease:Mendelian randomization study

The risk factors for nonalcoholic fatty liver disease (NAFLD) have not been clearly identified. We conducted a Mendelian randomization (MR) study to explore this. Independent genetic variants strongly associated with 5 lifestyle and 9 metabolic factors were selected as instrumental variables from corresponding genome-wide association studies (GWASs). Summary-level data for NAFLD were obtained from a GWAS meta-analysis of 8434 cases and 770,180 non-cases (discovery dataset) and another GWAS meta-analysis of 1483 cases and 17,781 non-cases (replication dataset). Univariable and multivariable MR analyses were performed. There were associations with NAFLD for lifetime smoking index (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.31-1.93 per SD-increase), body mass index (BMI, OR 1.33, 95% CI 1.23-1.43 per SD-increase), waist circumference (OR 1.82; 95% CI 1.48-2.24 per SD-increase), type 2 diabetes (OR 1.21, 95% CI 1.15-1.27 per unit increase in log-transformed odds), systolic blood pressure (OR 1.17; 95% CI 1.07-1.26 per 10 mmHg increase), high-density lipoprotein cholesterol (OR 0.84, 95% CI 0.77-0.90 per SD-increase), and triglycerides (OR 1.23, 95% CI 1.15-1.33 per SD-increase). The associations for type 2 diabetes, systolic blood pressure, triglycerides, but not for high-density lipoprotein cholesterol remained strong after adjusting for genetically-predicted BMI. Genetic liability to type 2 diabetes mediated 51.4% (95% CI 13.4-89.3%) of the BMI-effects on NAFLD risk. There were suggestive inverse associations of genetically-predicted alcohol, coffee, and caffeine consumption, and vigorous physical activity with NAFLD risk. This study identified several lifestyle and metabolic factors that may be causally implicated in NAFLD

The dynamic trends of HIV prevalence, risks, and prevention among men who have sex with men in

Objective. This study was to characterize the continuously changing trends of HIV prevalence, risks, sexual behaviors, and testing behaviors among men who have sex with men (MSM) in Chongqing, China. Methods. Five consecutive cross-sectional surveys were conducted among MSM in 2006MSM in , 2008MSM in , 2010MSM in , 2012MSM in , and 2013. Testing for HIV and syphilis was performed, and HIV risks, sexual behavior, prevention, and HIV testing behavior were collected using the same questionnaire. Results. HIV prevalence increased from 13.0% to 19.7% from 2006 to 2013 ( = 0.004), with an increase of 1.0% per year. Syphilis prevalence peaked in 2008 with a positive rate of 11.6% and then experienced a sharp drop to 2.8% in 2012 and 2.9% in 2013. Percentage of those who ever received HIV testing in the last year increased from 17.0% to 43.3% ( &lt; 0.001); condom use at the last anal intercourse and reported consistent condom use in the last 6 months increased from 51.8% to 71.0% ( &lt; 0.001) and from 24.7% to 47.9% ( &lt; 0.001), respectively. Conclusions. HIV continued to spread among MSM in Chongqing even when a decline in prevalence of syphilis and increase in awareness rate, condom use, and HIV testing seeking behaviors seemed to occur